FDA advisors weighed pediatric myopia data for Sydnexis amid widespread clinical use of atropine, but the panel backed a path that requires additional evidence to establish meaningful benefit. The discussion centered on whether the available dataset supported a regulatory threshold for the treatment. Despite support from clinicians for approval and real-world practices involving atropine, the panel favored another trial to clarify benefit magnitude. The recommendation underscores the gap between common prescribing habits and the specific comparative effectiveness showing expected for regulatory authorization. The decision trajectory is closely watched in pediatric eye care, where myopia progression and long-term risk management drive rapid adoption and payer scrutiny. If sponsors pursue the requested trial route, expectations for timing and endpoints may shift as additional benefit signals are sought.